Home
Products
Learn
About
Pricing
Log In

What are you looking for?

Home
Pricing
Compare AU

Compare AYLD vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P/ASX 200 Covered Call Complex ETF

ASX

Buy

Buy

Global X S&P Biotech ETF

ASX

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P/ASX 200 Covered Call Complex ETF (AYLD) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

AYLD

CURE

Popularity

Low

Low

Pearlers invested

13

78

Median incremental investment

$1,168.50

$640.11

Median investment frequency

Monthly

Monthly

Median total investment

$1,911.96

$1,274.70

Average age group

> 35

> 35


Key Summary

AYLD

CURE

Strategy

AYLD.AX was created on 2023-01-30 by Global X. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 68.43m in AUM and 203 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P/ASX BuyWrite Index

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 27.78m in AUM and 125 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

Commonwealth Bank of Australia (11.85 %)

BHP Group Ltd (8.28 %)

CSL Ltd (5.02 %)

Natera Inc (2.73 %)

Alnylam Pharmaceuticals Inc (2.65 %)

Vertex Pharmaceuticals Inc (2.64 %)

Top 3 industries

Financials (56.07 %)

Materials (16.72 %)

Health Care (10.14 %)

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

Australia (94.85 %)

United States (3.09 %)

New Zealand (1.58 %)

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.6 %

0.45 %


Key Summary

AYLD

CURE

Issuer

Global X

Global X

Tracking index

S&P/ASX 200 Index

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.6 %

0.45 %

Price

$10.14

$42.24

Size

$74.340 million

$28.994 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.18 %

4.24 %

Market

ASX

ASX

First listed date

31/01/2023

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

AYLD

CURE

Popularity

Low

Low

Pearlers invested

13

78

Median incremental investment

$1,168.50

$640.11

Median investment frequency

Monthly

Monthly

Median total investment

$1,911.96

$1,274.70

Average age group

> 35

> 35


Pros and Cons

AYLD

CURE

Pros

  • Higher exposure to AU market

  • Higher price growth

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

  • Lower exposure to AU market

  • Lower price growth

AYLD

CURE

Higher exposure to AU market

Lower exposure to AU market

Lower exposure to US market

Higher exposure to US market

Higher management fee

Lower management fee

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield